Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.

In inflammatory bowel disease (IBD), gut microvascular thrombosis as well as thromboembolic complications have repeatedly been observed. We examined the long-term course of markers of coagulation and fibrinolysis in relation to clinical disease activity.
In a prospective study, prothrombin fragment 1 and 2 (F1.2), thrombin-antithrombin complex (TAT), antithrombin, D-dimer, plasmin-alpha(2)-antiplasmin complex (PAP) and plasminogen activator inhibitor-1 (PAI-1) were measured in 20 patients with Crohn's disease (CD), 18 with ulcerative colitis (UC), and 19 with giant cell arteritis during active and inactive disease, as well as in 51 controls without inflammation.
Levels of F1.2, TAT, D-dimer, PAP and PAI-1 were significantly higher in active versus inactive CD and UC. However, even after 12 months of follow-up, in CD and UC the mean levels of F1.2, D-dimer and PAP were significantly higher than the levels of the controls.
Levels of F1.2, D-dimer and PAP were markedly raised for a long time in clinically inactive IBD, underlining a chronic state of hypercoagulation and enhanced fibrinolysis.
AuthorsAnton A Vrij, Joop Rijken, Jan W J van Wersch, Reinhold W Stockbrügger
JournalPathophysiology of haemostasis and thrombosis (Pathophysiol Haemost Thromb) 2003 Mar-Apr Vol. 33 Issue 2 Pg. 75-83 ISSN: 1424-8832 [Print] Switzerland
PMID14624048 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2003 S. Karger AG, Basel
Chemical References
  • Biomarkers
  • C-Reactive Protein
  • Adult
  • Aged
  • Biomarkers (blood)
  • Blood Coagulation
  • Blood Sedimentation
  • C-Reactive Protein (analysis)
  • Case-Control Studies
  • Colitis, Ulcerative (blood)
  • Crohn Disease (blood)
  • Female
  • Fibrinolysis
  • Giant Cell Arteritis (blood)
  • Humans
  • Inflammatory Bowel Diseases (blood)
  • Male
  • Middle Aged
  • Prospective Studies
  • Thrombophilia

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!

Choose Username:
Verify Password:
Enter Code Shown: